Kobo Biotech Profile
Key Indicators
- Authorised Capital ₹ 40.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 23.83 Cr
as on 16-11-2024
- Company Age 31 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 169.36 Cr
as on 16-11-2024
- Satisfied Charges ₹ 145.09 Cr
as on 16-11-2024
- Revenue -8.43%
(FY 2023)
- Profit 63.53%
(FY 2023)
- Ebitda 85.75%
(FY 2023)
- Net Worth -4.54%
(FY 2023)
- Total Assets -4.87%
(FY 2023)
About Kobo Biotech
- CIN/LLPIN
L24110TG1993PLC016112
- Company No.
016112
- Stock Symbol
BSE : 531541
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
03 Aug 1993
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Listed
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Kobo Biotech?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Neelam Murdia  | CFO | 14-Jun-2019 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Urja Shah | Director | 27-Dec-2018 | Current |
| Ajit Kamath | Director | 31-Jan-2009 | Current |
| Rajendra Kaimal | Director | 31-Jan-2009 | Current |
| Sunil Pitroda | Director | 05-Dec-2014 | Current |
Financial Performance and Corporate Structure Insights of Kobo Biotech.
Kobo Biotech Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 8.43% decrease. The company also saw a substantial improvement in profitability, with a 63.53% increase in profit. The company's net worth dipped by a decrease of 4.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kobo Biotech?
In 2022, Kobo Biotech had a promoter holding of 44.95% and a public holding of 55.04%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Arch Pharmalabs LimitedActive 31 years 8 monthsAjit Kamath, Rajendra Kaimal and 1 more are mutual person
- Arch Agro Industries Private LimitedActive 13 years 6 months
Ajit Kamath and Rajendra Kaimal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 29 Mar 2015 | ₹2.00 Cr | Open |
Indian Overseas Bank Creation Date: 11 Jan 2011 | ₹20.00 Cr | Open |
Others Creation Date: 10 Jul 2009 | ₹46.76 Cr | Open |
How Many Employees Work at Kobo Biotech?
Kobo Biotech has a workforce of 1 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kobo Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kobo Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
